These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32355309)

  • 1. Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.
    Cha PC; Satake W; Ando-Kanagawa Y; Yamamoto K; Murata M; Toda T
    J Hum Genet; 2020 Aug; 65(8):693-704. PubMed ID: 32355309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide.
    Naito T; Satake W; Cha PC; Kobayashi K; Murata M; Toda T
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):509-512. PubMed ID: 35264450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
    Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y
    J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parkinson's Disease: amantadine, zonisamide, dabrafenib].
    Okamoto T
    Brain Nerve; 2019 Sep; 71(9):953-959. PubMed ID: 31506397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
    Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M
    J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
    Ikeda K; Yanagihashi M; Miura K; Ishikawa Y; Hirayama T; Takazawa T; Kano O; Kawabe K; Mizumura N; Iwasaki Y
    J Neurol Sci; 2018 Aug; 391():5-9. PubMed ID: 30103971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
    Ueno SI; Saiki S; Fujimaki M; Takeshige-Amano H; Hatano T; Oyama G; Ishikawa KI; Yamaguchi A; Nojiri S; Akamatsu W; Hattori N
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.
    Kon T; Ueno T; Haga R; Tomiyama M
    Brain Behav; 2018 Aug; 8(8):e01036. PubMed ID: 29956879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
    Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
    Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
    Ueda Y; Tokashiki S; Kanemaru A; Kojima T
    Biochem Biophys Res Commun; 2012 Nov; 428(3):401-4. PubMed ID: 23103374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee.
    Hamza TH; Chen H; Hill-Burns EM; Rhodes SL; Montimurro J; Kay DM; Tenesa A; Kusel VI; Sheehan P; Eaaswarkhanth M; Yearout D; Samii A; Roberts JW; Agarwal P; Bordelon Y; Park Y; Wang L; Gao J; Vance JM; Kendler KS; Bacanu SA; Scott WK; Ritz B; Nutt J; Factor SA; Zabetian CP; Payami H
    PLoS Genet; 2011 Aug; 7(8):e1002237. PubMed ID: 21876681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.